What is the difference between ibrutinib/Eco and zanubrutinib?

Ibrutinib/Ibrutinib (Ibrutinib) and zanubrutinib (Zanubrutinib) are both BTK inhibitors and both play an important role in the field of targeted therapy of hematological tumors. However, there are certain differences between the two in drug design, indications, tolerance and application practice.

First of all, in terms of research and development background, ibrutinib is the first BTK inhibitor to be marketed in the world It pioneered BTK target therapy and accumulated a large amount of real-world evidence and international clinical experience. Zanubrutinib is a new generation of BTK inhibitor developed by local Chinese pharmaceutical companies. Its emergence not only breaks the monopoly of international pharmaceutical companies, but also promotes local innovative drugs to the international stage.

In terms of molecular structure and mechanism of action, both of them also target BTK. However, zanubrutinib pays more attention to selectivity in molecular optimization and reduces non-specific inhibition of other tyrosine kinases. This means that zanubrutinib may theoretically bring less cardiotoxicity and bleeding risks, thus showing certain advantages in terms of tolerability. As a first-generation drug, ibrutinib has been widely proven in terms of long-term efficacy, but some patients may experience discontinuation due to adverse reactions.

In terms of indications, the two have similar approval scopes in diseases such as chronic lymphocytic leukemia (CLL), SLL and WM, but zanubrutinib was approved later for some indications, which makes clinicians make choices based on drug availability and medical insurance policies in different patient groups. It is worth noting that ibrutinib has been widely included in the global medical insurance system, and zanubrutinib, as a rising star, is also accelerating to cover more countries and regions.

Taken together, ibrutinib remains an important representative of BTK inhibitors in clinical practice due to its long clinical application time and widely recognized efficacy. zanubrutinib's high selectivity and tolerability advantages make it an important supplement for subsequent treatment.

Reference materials:https://www.imbruvica.com/